To assess the persistence and long-term functionality of CD155 CAR-T cells, we performed a rechallenge assay in which CAR-T cells were exposed to fresh U937 or A549 tumor cells in 3 consecutive rounds over a total of 72 hours. The gene discussed is PVR; the disease is neoplasm.